Written question WQ97126
- Asked by
- Julie MorganLabour
- To be answered by
- Cabinet Secretary for Health and Social Care
- Tabled
- Due
- Answered
- Time to answer
- 6 days
Question
What are the new treatments available under the new treatment fund by year in this Senedd term?
Answer
Answered by Cabinet Secretary for Health and Social Care
In the period April 2021 to March 2025, 343 treatments have been made available through the New Treatment Fund.
Since April 2023, all details of medicines supported by the New Treatment Fund have been published by the All Wales Therapeutics and Toxicology Centre (AWTTC) and can be accessed at: The New Treatment Fund - All Wales Therapeutics and Toxicology Centre.
Treatments approved in 2021 and 2022 and the details of some medicines which have been approved since April 2025, are not included in the data published via the link above.
The medicines added to the New Treatment Fund between 2021 and 2023 (prior to the ATTWC publication link) are as follows:
Period: 2021-22
Treatment
Indication
Abemaciclib
Breast cancer
Adalimumab
Rheumatoid arthritis
Adalimumab
Ulcerative colitis
Amikacin liposomal
Nontuberculous mycobacterial (NTM) lung infections
Apalutamide
Metastatic prostate cancer
Apalutamide
Non-metastatic prostate cancer
Atezolizumab
Lung cancer
Atezolizumab
Urothelial cancer
Atidarsagene autotemcel
Metachromatic leukodystrophy
Avelumab
Urothelial cancer
Azacitidine
Leukaemia
Belimumab
Systemic lupus erythematosus
Bempedoic acid
Primary hypercholesterolaemia or mixed dyslipidaemia
Bempedoic acid-ezetimibe
Primary hypercholesterolaemia or mixed dyslipidaemia
Berotralstat
Hereditary angioedema
Bimekizumab
Psoriasis
Bortezomib
Multiple myeloma
Budesonide
eosinophilic oesophagitis
Cabotegravir
HIV
Cannabidiol
Seizures associated with tuberous sclerosis complex
Cenobamate
Epilepsy
Chlormethine gel
Lymphoma
Clostridium botulinum neurotoxin type A
Sialorrhoea due to neurological/neurodevelopmental disorders
Clostridium botulinum type A toxin-haemagglutinin complex
Focal spasticity
Conestat alfa
Hereditary angioedema
Cytarabine
Leukaemia
Dabigatran etexilate
Venous thromboembolic events
Dapagliflozin
Chronic kidney disease
Daratumumab
Multiple myeloma
Dexamethasone
Multiple myeloma
Diroximel fumarate
Multiple sclerosis
Dolutegravir
HIV
Dostarlimab
Endometrial cancer
Dupilumab
Severe asthma
Elosulfase alfa
Mucopolysaccharidosis
Empagliflozin
Heart failure
Entrectinib
Lung cancer
Entrectinib
Solid tumours
Enzalutamide
Prostate cancer
Etanercept
Rheumatoid arthritis
Etravirine
HIV
Everolimus
Refractory partial-onset seizures
Fedratinib
Disease-related splenomegaly/myelofibrosis
Filgotinib
Ulcerative colitis
Fremanezumab
Migraine
Fulvestrant
Breast cancer
Givosiran
Acute hepatic porphyria
Glecaprevir/pibrentasvir
Hepatitis C
Guselkumab
Psoriatic arthritis
Inclisiran
Hypercholesterolaemia
Indacaterol acetate/glycopyrronium bromide/mometasone furoate
Asthma
Infliximab
Rheumatoid arthritis
Ipilimumab
Colorectal cancer
Ipilimumab
Renal cancer
Ixekizumab
Axial spondyloarthritis
Mexiletine
Myotonia
Midostaurin
Mastocytosis
Mogamulizumab
Mycosis fungoides and Sézary syndrome
Nintedanib
Progressive fibrosing interstitial lung diseases
Niraparib
Ovarian fallopian tube and peritoneal cancer
Nitisinone
Alkaptonuria
Nivolumab
Colorectal cancer
Nivolumab
Lung cancer
Nivolumab
Oesophageal & gastro-oesophageal junction cancer
Nivolumab
Oesophageal cancer
Nivolumab
Renal cancer
Nivolumab
Squamous cell carcinoma
Odevixibat
Intrahepatic cholestasis
Onasemnogene abeparvovec
Spinal muscular atrophy
Osimertinib
Lung cancer
Palforzia
Peanut allergy
Pegcetacoplan
Paroxysmal nocturnal haemoglobinuria
Pembrolizumab
colorectal cancer
Pembrolizumab
Hodgkin lymphoma
Pembrolizumab
Lung cancer
Pembrolizumab
Melanoma
Pembrolizumab
Oesophageal & gastro-oesophageal junction cancer
Pemigatinib
Cholangiocarcinoma
Perampanel
Seizures
Ponesimod
Multiple sclerosis
Ravulizumab
Atypical haemolytic uraemic syndrome
Ravulizumab
Paroxysmal nocturnal haemoglobinuria
Rilpivirine
HIV
Risdiplam
Spinal muscular atrophy
Rivaroxaban
venous thromboembolism
Romosozumab
Severe osteoporosis
Sapropterin
Phenylketonuria
Secukinumab
Axial spondyloarthritis
Secukinumab
Psoriasis
Selpercatinib
Lung cancer
Selpercatinib
Thyroid cancer
Selumetinib
Plexiform neurofibromas
Solriamfetol
Daytime sleepiness caused by narcolepsy
Sotorasib
Lung cancer
Tepotinib
Lung cancer
Thalidomide
Multiple myeloma
Tirbanibulin
Keratosis
Tofacitinib
Juvenile idiopathic arthritis
Tucatinib
Breast cancer
Upadacitinib
Psoriatic arthritis
Upadacitinib
Rheumatoid arthritis
Ustekinumab
Plaque psoriasis
Venetoclax
Leukaemia
2022-23
Treatment
Indication
Abemaciclib
Breast cancer
Abrocitinib
Dermatitis
Alpelisib
Breast cancer
Ambrisentan
Hypertension
Asciminib
Leukaemia
Asfotase alfa
Hypophosphatasia
Ataluren
Duchenne muscular dystrophy
Atezolizumab
Lung cancer
Avacopan
Granulomatosis with polyangiitis or microscopic polyangiitis
Avalglucosidase alfa
Pompe disease
Avatrombopag
Thrombocytopenia
Axicabtagene ciloleucel
Lymphoma
Azacitidine
Acute myeloid leukaemia
Bedaquiline
Tuberculosis
Bevacizumab
Carcinoma of the cervix
Brexucabtagene autoleucel
Leukaemia
Brivaracetam
Epilepsy
Brolucizumab
Diabetic macular oedema
Cabozantinib
Hepatocellular carcinoma
Cannabidiol
Tuberous sclerosis complex
Cariprazine
Schizophrenia
Cemiplimab
Squamous cell carcinoma
Daratumumab
Multiple myeloma
Dexamethasone
Diabetic macular oedema
Difelikefalin
Pruritus
Dupilumab
Asthma
Durvalumab
Lung cancer
Eladocagene exuparvovec
L-amino acid decarboxylase deficiency
Elbasvir-grazoprevir
Hepatitis C
Eptinezumab
Migraine
Everolimus
Renal angiomyolipoma and subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Faricimab
Diabetic macular oedema
Faricimab
Wet age-related macular degeneration
Fenfluramine
Dravet syndrome
Ferric maltol
Iron deficiency
Finerenone
Kidney disease
Fostamatinib
Thrombocytopenia
Guselkumab
Psoriatic arthritis
Hydrocortisone
Adrenal hyperplasia
Ibrutinib
Leukaemia
Icosapent ethyl
Cardiovascular events
Imlifidase
Kidney disease
Insulin degludec
Diabetes mellitus
Ipilimumab
Pleural mesothelioma
Ixazomib
Multiple myeloma
Lacosamide
Epilepsy
Lenvatinib
Renal cell carcinoma
Lumasiran
Hyperoxaluria
Maribavir
Cytomegalovirus
Mercaptamine bitartrate
Nephropathic cystinosis
Migalastat hydrochloride
Fabry disease
Mobocertinib
Lung cancer
Nintedanib
Pulmonary fibrosis
Nirmatrelvir-ritonavir
COVID-19
Nivolumab
gastric gastro-oesophageal junction or oesophageal adenocarcinoma
Nivolumab
Lung cancer
Nivolumab
Oesophageal squamous cell carcinoma
Nivolumab
Pleural mesothelioma
Nivolumab
Urothelial cancer
Onasemnogene abeparvovec
Spinal muscular atrophy
Ozanimod
Ulcerative colitis
Palbociclib
Breast cancer
Pembrolizumab
Breast cancer
Pembrolizumab
Cervical cancer
Pembrolizumab
Melanoma
Pembrolizumab
Renal cancer
Pembrolizumab
Renal cell carcinoma
Polatuzumab vedotin
Lymphoma
Regorafenib
Colorectal cancer
Relugolix – estradiol - norethisterone acetate
Uterine fibroids
Risankizumab
Arthritis
Rituximab
Pemphigus vulgaris
Roxadustat
Anaemia in kidney disease
Sacituzumab govitecan
Breast cancer
Setmelanotide
Obesity
Sofosbuvir - velpatasvir
Hepatitis
Somatrogon
Growth disturbance
Sotrovimab
COVID-19
Teduglutide
Short bowel syndrome
Teriflunomide
Multiple sclerosis
Tezepelumab
Asthma
Tocilizumab
COVID-19
Tralokinumab
Dermatitis
Trastuzumab deruxtecan
Breast cancer
Trifluridine-tipiracil
Gastric cancer or gastro-oesophageal junction adenocarcinoma
Upadacitinib
Ankylosing spondylitis
Upadacitinib
Axial spondyloarthritis
Upadacitinib
Dermatitis
Upadacitinib
Ulcerative colitis
Venetoclax
Leukaemia
Voclosporin
Lupus nephritis
Vutrisiran
Amyloidosis
Zanubrutinib
Waldenström's macroglobulinaemia